BioCentury
ARTICLE | Finance

Third Rock's Lotus position

Third Rock plans fast track for Lotus, a series A Orphan disease play

July 4, 2011 7:00 AM UTC

Third Rock Ventures is hoping to get from bench to proof of concept in a little more than three years with protein replacement company Lotus Tissue Repair Inc.

The firm was the sole investor in last week's tranched $26 million series A round...